** Drug developer Altimmune's ALT.O shares rise ~2% to $8.05 premarket
** Company says its shares will be added to Nasdaq Biotechnology index .NBI before market opens on Dec. 23
** Company currently testing pemvidutide for treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH)
** Avg rating of brokerages covering Altimmune stock is "buy"; median PT $24 - LSEG
** As of last close, company's shares have fallen 29.8% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。